BioAge Labs, Inc. (BIOA) Form 8-K — Aug 5, 2026
BioAge Labs reported a Q2 2026 net loss of $26.1 million, or $0.58 per share, versus a $21.6 million loss, or $0.60 per share, in the year-ago quarter, as R&D spending rose to $24.4 million from $19.8 million on BGE-102 trial activity. Collaboration revenue was flat at $2.4 million. The company ended the quarter with approximately $381.3 million in cash, cash equivalents and marketable securities, which management expects will fund operations and capital expenses through 2029.
Key figures
- Revenue
- $2.4 million
- Total Assets
- 396929000
- Cash Position
- $381.3 million (cash, cash equivalents, and marketable securities as of June 30, 2026)
- Shares Outstanding
- 45776902
- Cash Runway
- through 2029
- Quell Dme Data
- mid-2027
- Net Loss Q22025
- $21.6 million
- Ga Expense Q22026
- $7.4 million
- Rnd Expense Q22025
- $19.8 million
- Rnd Expense Q22026
- $24.4 million
- Quell Cv Enrollment
- approximately 160 adults with obesity and elevated baseline inflammation
- Quell Cv Topline Data
- second half of 2026
- Bge102 Hs Crp Reduction
- median 86% from baseline at 60 mg and 120 mg once daily
- Bge102 Il1b Suppression
- up to 98%
- Collaboration Revenue Q22025
- $2.4 million
- Weighted Average Shares Q22025
- 35850037
- Weighted Average Shares Q22026
- 44838893
Price after filing
Close on the filing date to close N calendar days later (from $11.20). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.